

Dear EML Secretariat,

On behalf of the <u>Cluster Kopfschmerzen Verein Österreich</u>, a patient organization dedicated to supporting individuals and families affected by cluster headaches, I am writing to express our strong support for the inclusion of new migraine and cluster headache treatments in the WHO Essential Medicines List.

We have reviewed the applications with great interest, particularly:

- **A.10** Eletriptan + Naproxen (Migraine)
- A.13 Fremanezumab (High frequency and chronic migraine)
- **I.2** Amitriptyline (Migraine prophylaxis)
- **I.3** Bisoprolol (Migraine prophylaxis)
- **I.7** Ibuprofen (Acute migraine treatment)
- **I.10** Prednisolone, Sumatriptan, and Verapamil (Cluster headache)

Cluster headache and migraine are severely disabling neurological conditions that remain underdiagnosed and undertreated worldwide. The addition of these medications to the WHO Essential Medicines List would be a crucial step toward improving access to effective treatments, ensuring better care for millions of patients globally.

As an organization committed to advocating for headache patients in Austria, we fully support this initiative and are available to provide any further information or assistance. We strongly urge the WHO to recognize the urgent need for these medications in clinical practice.

We appreciate your attention to this matter and look forward to the positive impact this decision will have on global health.

Sincerely,

Stefan Kohlweg

Chairman

Cluster Headache Association Austria